KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to -$11.5 million.

  • West Pharmaceutical Services' Cash from Financing Activities rose 8214.29% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.3 million, marking a year-over-year increase of 6739.77%. This contributed to the annual value of -$622.6 million for FY2024, which is 3546.56% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' Cash from Financing Activities stood at -$11.5 million, which was up 8214.29% from -$14.9 million recorded in Q2 2025.
  • West Pharmaceutical Services' Cash from Financing Activities' 5-year high stood at $300000.0 during Q2 2021, with a 5-year trough of -$271.0 million in Q1 2024.
  • For the 5-year period, West Pharmaceutical Services' Cash from Financing Activities averaged around -$90.4 million, with its median value being -$68.9 million (2024).
  • In the last 5 years, West Pharmaceutical Services' Cash from Financing Activities soared by 13333.33% in 2021 and then crashed by 1216666.67% in 2022.
  • West Pharmaceutical Services' Cash from Financing Activities (Quarter) stood at -$6.2 million in 2021, then plummeted by 53.23% to -$9.5 million in 2022, then plummeted by 1894.74% to -$189.5 million in 2023, then skyrocketed by 63.64% to -$68.9 million in 2024, then surged by 83.31% to -$11.5 million in 2025.
  • Its Cash from Financing Activities stands at -$11.5 million for Q3 2025, versus -$14.9 million for Q2 2025 and -$147.0 million for Q1 2025.